Chain Bridge I · OTC:CBRRF
Chain Bridge I — SPAC Merger (July 2024)
41 slides from Chain Bridge I's SPAC merger presentation, Jul 30, 2024
Slide 1: July 29, 2024
July 29, 2024 CONFIDENTIAL - DO NOT DISTRIBUTE 1
Slide 2: Disclaimers: Important Information for Investors
DISCLAIMERS Important Information for Investors This investor presentation (this “Presentation”) (references to which shall be deemed to include any information which has be en or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) relates to a
Slide 3: Disclaimers: Forward-Looking Statements
DISCLAIMERS These forward - looking statements are subject to a number of risks and uncertainties, including ( i ) changes in domestic and foreign business, market, financial, political and legal conditions; (ii) the ability of the partie s t o successfully or timely consummate the Transaction, incl
Slide 4: Disclaimers: Participants in the Solicitation
DISCLAIMERS Participants in the Solicitation CBRG, Phytanix and their respective directors and executive officers may be deemed under SEC rules to be participants in the sol icitation of proxies of CBRG’s stockholders in connection with the Transaction. Investors and security holders may obtain mo
Slide 5: Cannabinoid & Cannabis-Based Pharmaceuticals: Market Opportunity
CANNABINOID & CANNABIS - BASED PHARMACEUTICALS: Market Opportunity CONFIDENTIAL - DO NOT DISTRIBUTE 5 • The development of cannabinoid medicines offers the potential for high return on investment • GW Pharma acquired by Jazz Pharmaceuticals for US $7.2 Billion 1 • Epidiolex (DS, LGS & TSC indication
Slide 6: Scientific Team
CONFIDENTIAL - DO NOT DISTRIBUTE 6 SCIENTIFIC TEAM CONFIDENTIAL - DO NOT DISTRIBUTE Colin Stott - Chief Operating Officer • Medicinal & Pharmaceutical Chemist / Preclinical & Clinical Development Specialist • 19 years with GW Pharma as R & D Operations Director (17 years) and latterly Scientific Aff
Slide 7: Phytanix's Therapeutic Areas of Focus
PHYTANIX’S THERAPEUTIC AREAS OF FOCUS: CONFIDENTIAL - DO NOT DISTRIBUTE INDICATION 1 TREATMENT OF BLADDER PAIN SYNDROME (PAIN & URINARY SYMPTOMS) INDICATION 2 DEVELOPMENT OF A “SIMPLIFIED”CANNABIS EXTRACT (akin to SATIVEX®) DEVELOP AS PER FDA & EMA GUIDANCE (akin to SATIVEX®) TREATMENT OF TREATMENT
Slide 8: Bladder Pain Syndrome Indication: Estimated Project Specific Costs
BLADDER PAIN SYNDROME (BPS) INDICATION: Estimated Project Specific Costs Through Development Lifecycle Bladder Pain Syndrome (BPS) Indication Amended from: Valuing drugs and biotech companies (baybridgebio.com) Project Specific Direct Costs to Start of Phase 1 $7.1M USD; 15 Months Project Specific
Slide 9: Rationale for Selection of BPS Indication: Commercial Rationale
RATIONALE FOR SELECTION OF BPS INDICATION: Commercial Rationale CONFIDENTIAL - DO NOT DISTRIBUTE 9 1) Large potential market • 3 to 8 million women in the United States may have IC - That is about 3 to 6% of ALL WOMEN in the US 1 • 1 to 4 million men may have IC too 1 2) There are very few FDA appro
Slide 10: Rationale for BPS Indication: Preclinical Rationale (1)
RATIONALE FOR SELECTION OF BPS INDICATION: Preclinical Rationale (1) • Cannabinoid receptors are found in the bladder 1 • Cannabinoid receptor expression in the bladder is altered in bladder overactivity 2 • CB1 Knockout mice have a higher urinary frequency and more spontaneous activity than normal
Slide 11: Rationale for BPS Indication: Preclinical Rationale (2)
RATIONALE FOR SELECTION OF BPS INDICATION: Preclinical Rationale (2) • In vivo a CB1 & CB2 receptor agonist CP55,940 increased the micturition (urinary) interval by 46% and threshold pressure by 124% 1 • In vivo, a non - selective cannabinoid agonist significantly reduced the afferent nerve activity
Slide 12: Rationale for BPS Indication: Clinical Rationale RCT Pain Data
RATIONALE FOR SELECTION OF BPS INDICATION: Clinical Rationale Randomized Controlled Clinical Trial (RCT) Pain Data CONFIDENTIAL - DO NOT DISTRIBUTE 12
Slide 13: Rationale for BPS Indication: RCT Pain Data 3
RATIONALE FOR SELECTION OF BPS INDICATION: RCT Pain Data CONFIDENTIAL - DO NOT DISTRIBUTE 13
Slide 14: Rationale for Bladder Pain Syndrome Indication: Clinical Rationale
RATIONALE FOR SELECTION OF BLADDER PAIN SYNDROME INDICATION Clinical Rationale: 1. An open - label study of Sativex and THC Extract demonstrated activity after 8 weeks treatment in MS patients with bladder dysf unction • Patients took extracts containing delta - 9 - tetrahydrocannabinol (THC) and ca
Slide 15: Randomised Controlled Trials - Bladder Data
CONFIDENTIAL - DO NOT DISTRIBUTE 15 All but one of the secondary endpoints were statistically in favour of THC: CBD in this study RATIONALE FOR SELECTION OF BPS INDICATION: Randomised, Controlled Trials (RCTs) - Bladder Data SATIVEX has already shown to be effective in an RCT of Bladder Dysfunction
Slide 16: Intellectual Property Protection for BPS Indication
INTELLECTUAL PROPERTY PROTECTION FOR BPS INDICATION • Dominic Schiller built a robust and effective Intellectual Property position covering Sativex (a cannabis - based medicine made fr om complex cannabis extracts) used to tread spasticity in MS and Epidiolex (a highly purified CBD) used to treat se
Slide 17: Cannabis Based Medicines Can Get Through Phase 1: Single & Multiple Dose
CANNABIS BASED MEDICINES CAN SUCCESSFULLY GET THROUGH CLINICAL PHASE 1: Single & Multiple Dose Study CONFIDENTIAL - DO NOT DISTRIBUTE 17
Slide 18: Cannabis Based Medicines Phase 1: Fed v Fasted PK Study
CANNABIS BASED MEDICINES CAN SUCCESSFULLY GET THROUGH CLINICAL PHASE 1: Fed v Fasted Pk Study CONFIDENTIAL - DO NOT DISTRIBUTE 18
Slide 19: Typical Pharmaceutical Development Timeline
TYPICAL PHARMACEUTICAL DEVELOPMENT TIMELINE: Time From Project Start To Regualtory Application For Clinical Phase 1 CONFIDENTIAL - DO NOT DISTRIBUTE 19
Slide 20: Potential Manufacturing Partners for Product Development
POTENTIAL MANUFACTURING PARTNERS FOR PRODUCT DEVELOPMENT BPS / IC Project United Science Holdings (Osceola, Wisconsin) • Capable of producing Botanical Extracts and Ingredients/ High Purity Isolates • Cannabinoids, Terpenes, Flavonoids, Alkaloids, Xanthins • Extraction Equipment (can handle up to 3
Slide 21: Potential CRO Partners for Preclinical / Product Development
POTENTIAL CRO PARTNERS FOR PRECLINICAL / PRODUCT DEVELOPMENT (formerly Covance) – UK, Germany, US, Singapore & China locations • Labcorp did much of the preclinical development for Sativex and all of it for Epidiolex. • Very experienced in the setup, validation and bioanalysis of cannabinoids in pla
Slide 22: TRFSA Indication: Estimated Project Specific Costs
TREATMENT - RESISTANT FOCAL SEIZURES IN ADULTS ( T RFSA) INDICATION: Estimated Project Specific Costs Through Development Lifecycle Amended from: Valuing drugs and biotech companies (baybridgebio.com) $7.5M USD; 15 Months $9.0M USD; 21 Months $17.2M USD; 36+ Months Assumptions: 1) Only 1 Ph 1
Slide 23: Rationale for Selection of TRFSA Indication: Commercial Rationale
RATIONALE FOR SELECTION OF TRFSA INDICATION: Commercial Rationale: CONFIDENTIAL - DO NOT DISTRIBUTE 23 1) Large potential market • In a systematic review and meta - analysis of the prevalence and incidence of epilepsy: • active generalized epilepsy was found to be the most prevalent (4.33 per 1,000
Slide 24: Rationale for TRFSA Indication: Preclinical Rationale
RATIONALE FOR SELECTION OF TRFSA INDICATION: Preclinical Rationale: CONFIDENTIAL - DO NOT DISTRIBUTE 24 0 100 200 300 400 500 600 700 Vehicle Diazepam (30mg/kg) Product 1 (200mg/kg) Product 2 (200mg/kg) CBD (100mg/kg) Latency to Tonic Hindlimb Seizure (seconds) Tonic Hindlimb Seizures **** *** ****
Slide 25: Rationale for TRFSA Indication: Clinical Rationale (1)
RATIONALE FOR SELECTION OF TRFSA INDICATION: Clinical Rationale (1) CONFIDENTIAL - DO NOT DISTRIBUTE CBD IS EFFECTIVE IN MULTIPLE RANDOMIZED, DOUBLE - BLIND PLACEBO - CONTROLLED CLINICAL STUDIES OF SEZIURE 25
Slide 26: Rationale for TRFSA Indication: Clinical Rationale (2)
RATIONALE FOR SELECTION OF TRFSA INDICATION: Clinical Rationale (2) CONFIDENTIAL - DO NOT DISTRIBUTE 26
Slide 27: Kochen et al. 2023: CBD Adjuvant Treatment in Drug-Resistant Focal Epilepsy
Kochen et al. 2023: CBD as an adjuvant treatment in adults with drug - resistant focal epilepsy • Worsening (increase number of seizures), • Non - responders = (decrease number of seizures between 0 – 50%), • R esponders (decrease number of seizures by 50% or more) CONFIDENTIAL - DO NOT DISTRIBUTE 2
Slide 28: Jazz Pharmaceuticals: CBD in Focal Seizures, AES 2023
Jazz Pharmaceuticals: CBD in Focal Seizures : American Epilepsy Society (AES) 2023 • Effect of CBD (Epidiolex®) in Treatment resistant Focal Seizures • CBD (Epidiolex®) produces a 62% reduction in focal seizures after 144 weeks of treatment (Expanded Access Program) • At least 50% reduction (respond
Slide 29: Park et al. AES 2023: Long-Term Effectiveness of CBD Against Focal-Onset Seizures
Park et al. AES 2023: Long - Term Effectiveness of CBD Against Focal - Onset Seizures in Treatment - Resistant Epilepsies (TRE) CONFIDENTIAL - DO NOT DISTRIBUTE 29
Slide 30: Park et al. AES 2023: Long-Term Effectiveness of CBD Against Focal-Onset Seizures
Park et al. AES 2023: Long - Term Effectiveness of CBD Against Focal - Onset Seizures in Treatment - Resistant Epilepsies (TRE) CONFIDENTIAL - DO NOT DISTRIBUTE 30 • CBD (Epidiolex®) produces a 94% reduction in Focal Aware Seizures (FAS) after 144 weeks of treatment (Expanded Access Program) • CBD (
Slide 31: Park et al. AES 2023: 50%, 75% and 100% Response Rates
AES = American Epilepsy Society TRE = Treatment - Resistant Epilepsies CONFIDENTIAL - DO NOT DISTRIBUTE 31 Park et al. AES 2023: Long - Term Effectiveness of CBD Against Focal - Onset Seizures in TRE (50%, 75% and 100% Response Rates) 50% Responders 7 5% Responders 10 0% Responders
Slide 32: Park et al. AAN 2024: Long-Term Effectiveness of CBD Against Focal-Onset Seizures
Park et al. AAN 2024: Long - Term Effectiveness of CBD Against Focal - Onset Seizures in TRE (50%, 75% and 100% Response Rates) ABSTRACT ( https://index.mirasmart.com/AAN2024/SearchResults.php?Author_Institution=&Program_Number=&Topic=&Session_Name=&Author=Park%2C +Yo ng&Title= ) • Long - term Effec
Slide 33: Phytanix Intellectual Property (1)
PHYTANIX INTELLECTUAL PROPERTY (1) Phytanix patent families: • PTX0001 Patent Family • “ Terpenophenolic Compounds And Their Use” • Patent has been Granted • PTX0002 Patent Family • “ Terpenophenolic Scaffolds and a Method for Producing Same” • This patent builds on PTX001 family and covers more tha
Slide 34: Phytanix Intellectual Property (2): Patent Family Status
PHYTANIX INTELLECTUAL PROPERTY (2) Patent Family Status Patent Family Ref Patent Owner Country Filing Date Filing Code Nat/Reg entry Date Nat/Reg entry Number PTX P0001 AUw Phytotherapeutix Ltd* Australia 31 March 2021 PCT/GB2021/050812 28 October 2022 2021248627 PTX P0001 BRw Phytotherapeutix Ltd B
Slide 35: Formulation Technology In-Licensed by Phytanix
FORMULATION TECHNOLOGY IN - LICENSED BY PHYTANIX : Leucine improves the dissolution rate of a formulation of Ibuprofen • Leucine improves the dissolution rate of a formulation of Ibuprofen • Dissolution rate is a marker of increased oral bioavailability • Leucine increases the flowability of the pow
Slide 36: Phytanix Inc. - Proposed Operating Structure
PHYTANIX INC. – PROPOSED OPERATING STRUCTURE CONFIDENTIAL - DO NOT DISTRIBUTE 36 COO Colin Stott CMO (TBA) CIPO Dominic Schiller CFO (TBA) CEO Barrett Evans Executive Management Team Senior Management Team Analytical Services Director (In discussions) Regulatory Affairs Director (in discussions) Cli
Slide 37: Recruitment: The Benefit of Experience in the Cannabinoid Pharma Industry
UNITED STATES HIRES EX - US (UK, & AUSTRALIA) HIRES ALETROLA RECRUITMENT: The Benefit of Experience in t he Cannabinoid Pharma Industry 37 Regulatory Affairs VP / Director Regulatory Affairs (ex - GW Reg Affairs >5 years CB experience) - In discussions Regulatory Affairs Manager (ex - GW Reg Affairs
Slide 38: Any Questions?
ANY QUESTIONS ? CONFIDENTIAL - DO NOT DISTRIBUTE 38
Slide 39: Appendix
July 29, 2024 CONFIDENTIAL - DO NOT DISTRIBUTE 39 APPENDIX
Slide 40: Schedule Status of Cannabis in the USA
Schedule 1 Status of Cannabis in the USA • Cannabis is currently scheduled as Schedule 1 by the DEA under Federal Law (Controlled Substances Act 1970 & amendments) • Under the law this means that it has “No medical value” • Discussion as to whether the DEA will reschedule cannabis to Schedule 2 or S
Slide 41: Asset Purchase / In-Licensing Agreements in Place
ASSET PURCHASE / IN - LICENSING AGREEMENTS IN PLACE • Phytanix has a number of Licensing / Asset Purchase Agreements in place: • Ferven Asset Purchase Agreement • The terms of this agreement enables Ferven (and thus Alterola) to use a specific micro - organism for genetic engineering for the product